GFHT (@GFHT_Hemostase) header
GFHT (@GFHT_Hemostase) profile picture

GFHT

@GFHT_Hemostase

Compte clos. Suivez-nous désormais sur @SFTHemostase, nouvelle société savante née du Groupe Français d'études sur l'Hémostase et la Thrombose et de la CoMETH

 Paris, France
geht.org
Joined March 2016
  • Tweets1.1K
  • Following88
  • Followers605
54Media
Photo by GFHT (@GFHT_Hemostase)Photo by GFHT (@GFHT_Hemostase)Photo by GFHT (@GFHT_Hemostase)Photo by GFHT (@GFHT_Hemostase)Photo by GFHT (@GFHT_Hemostase)Photo by GFHT (@GFHT_Hemostase)Photo by GFHT (@GFHT_Hemostase)Photo by GFHT (@GFHT_Hemostase)Photo by GFHT (@GFHT_Hemostase)Photo by GFHT (@GFHT_Hemostase)
Suivez-nous désormais sur @SFTHemostase ! @SFAR_ORG @SFMV @GIHP_official @AnticoagForum @isth @EHA_Hematology
5
5
539
GFHT retweeted
SFMV (@lasfmv) profile picture
SFMV
@lasfmv6 Jul 2023
Remboursement des auto INR pour les patients nécessitant un traitement anticoagulant au long cours et pour lesquels les AODs sont contre-indiqués ou non indiqués. Prescription possible par les médecins vasculaires ! La HAS s'était déjà prononcée en la faveur de cette extension depuis le 06/12/22, extension validée par le CEPS et arrêtés parus dans le Journal Officiel cette semaine qui prendront effet le 17/07/23 Lien : has-sante.fr/jcms/p_3400581/…
Image from SFMV (@lasfmv)
11
1
16
1,479
GFHT retweeted
NEJM (@NEJM) profile picture
NEJM
@NEJM14 Jun 2023
Editorial: Tranexamic Acid for Trauma Patients — More Lives to Save and Outcomes to Consider nej.md/3NmSVZf
Tranexamic Acid for Trauma Patients — More Lives to Save and Outcomes to Consider | NEJM

Tranexamic Acid for Trauma Patients — More Lives to Save and Outcomes to Consider | NEJM

Traumatic hemorrhage accounts for approximately 2 million deaths each year worldwide.1 In 2010, the results of the Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage (CRASH)–2...

nejm.org
18
1
40
33,191
GFHT retweeted
NEJM (@NEJM) profile picture
NEJM
@NEJM14 Jun 2023
Late breaking at #CCR23: In the PATCH-Trauma trial involving adults with major trauma, treatment with tranexamic acid did not result in a greater number of patients surviving with a favorable functional outcome at 6 months than placebo. nej.md/43zNuMj
Levels on the Glasgow Outcome Scale–Extended (GOS-E) at 6 Months. The GOS-E ranges from 1 to 8, with higher levels indicating better outcomes. The percentages represent the percentage of patients with each level. No patients in the tranexamic acid group had a GOS-E level of 2. The dotted line indicates the demarcation between death or survival with an unfavorable functional outcome (GOS-E levels of 1 to 4) and survival with a favorable functional outcome (GOS-E levels of 5 to 8). Results are shown without imputation; the results of an analysis that used imputation are provided in Figure S3 in the Supplementary Appendix. Percentages may not total 100 because of rounding.

ALT Levels on the Glasgow Outcome Scale–Extended (GOS-E) at 6 Months. The GOS-E ranges from 1 to 8, with higher levels indicating better outcomes. The percentages represent the percentage of patients with each level. No patients in the tranexamic acid group had a GOS-E level of 2. The dotted line indicates the demarcation between death or survival with an unfavorable functional outcome (GOS-E levels of 1 to 4) and survival with a favorable functional outcome (GOS-E levels of 5 to 8). Results are shown without imputation; the results of an analysis that used imputation are provided in Figure S3 in the Supplementary Appendix. Percentages may not total 100 because of rounding.

3
155
39
306
239,888
Antithrombotic Treatment in Patients With Hemophilia: an EHA-ISTH-EAHAD-ESO Clinical Practice Guidance journals.lww.com/hemasphere/…
Antithrombotic Treatment in Patients With... : HemaSphere

Antithrombotic Treatment in Patients With... : HemaSphere

Cardiovascular disease is an emerging medical issue in patients with hemophilia (PWH) and its prevalence is increasing up to 15% in PWH in the United...

ovid.com
5
1
10
1,155
Check out this new #RPTHReview on the safety of hormonal therapies in those with blood disorders. @teengynheme @bsamuelson_md @RosovskyRachel @LakshmiSrivaths @fwgbd bit.ly/3MVBmhG
Image from RPTH (@RPTHjournal)
17
48
8,138
Covidose a parlé ! Pas d’augmentation des doses d’anticoagulant pour prévenir la maladie thromboembolique veineuse dans la Covid-19. Bravo @szuily @INNOVTE1 thelancet.com/pdfs/journals/… youtu.be/SJwQm6_LR3g
5
16
1,223
The use of antithrombotic drugs in #hemophilia guidance document has been published with an accompanying commentary by @HermansCedric in the journal @Hemasphere_EHA. tinyurl.com/72jss9m3 @EAHADnews @EHC_Haemophilia @isth
Image from Michael Makris (@ProfMakris)
Image from Michael Makris (@ProfMakris)
29
58
6,596
💉🩸Our latest paper in @RPTHjournal about Dabigatran-reversal failure using #Idarucizumab ➡️Baseline dabigatran level could help in anticipating dabigatran-#Reversal failure and/or rebound. 🧪 @BilloirP @DavidMSmadja @DorotheeFaille @HopitalPompidou sciencedirect.com/science/ar…
1
4
3
15
4,230
Recommandations pour le titrage des inhibiteurs anti-FVIII et anti-FIX onlinelibrary.wiley.com/shar…
1
1
2
486
Our “MORPHEUS” project (PROGNOSIS IMPROVEMENT OF UNPROVOKED VENOUS THROMBOEMBOLISM USING PERSONALIZED ANTICOAGULANT THERAPY) is accepted on the European call HORIZON-HLTH-2022-TOOL-11-01. French @INNOVTE1 network and 8 european countries will conduct this project. A dream team.
7
14
4
41
4,215
‼️ The Anexxa-I study has been terminated early for meeting superiority criteria for hemostatic efficacy vs usual care ‼️ astrazeneca.com/media-centre…

Andexxa Phase IV trial stopped early after achieving pre-specified criteria on haemostatic efficacy...

astrazeneca.com
8
15
1
38
15,432
Pas d'intérêt des HBPM chez les femmes présentant des fausses couches récurrentes et une thrombophilie héréditaire. Le dépistage de la thrombophilie héréditaire chez ces femmes n'est pas indiqué. #ALIFE2 @ALIFE2trial
1
1
6
260
Today the ALIFE2 Trial was published in @TheLancet - thank you to all the women who participated and colleagues who supported the trial authors.elsevier.com/c/1hAoh…
7
2
22
3,363
Image from GFHT (@GFHT_Hemostase)
8
1
22
2,620
🚨 Les inscriptions pour le congrès annuel de la SFAR sont ouvertes ! Inscrivez-vous dès maintenant ➡️ sfar-lecongres.com/inscripti… @SFARJeunes @AJARFrance @SyndicatSnarf @SNPHARE @SNJeunesAR @jeunesMIR @contactfnir @cnear_fr @ISNItwit @fnasapr @IADE_de_France @SNIA75
Image from SFAR Anesthésie Réanimation (@SFAR_ORG)
16
2
18
4,947
ashpublications.org/bloodadv…
American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombop...

American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombop...

Background. Hereditary and acquired thrombophilia are risk factors for venous thromboembolism (VTE). Whether testing helps guide management decisions is co

ashpublications.org
1
215
Merci à toute l’équipe. Un excellent cru ! On est toujours triste quand cela se termine. À bientôt @mhemo @cfh_2023 @gfht @LentingPeter @cecile_denis @caterinacasari @ODChristophe1
Image from sophie susen (@sophie_susen)
5
21
795
Merci a tous!!!!!
Image from Congrès de la SFTH (@SFTH_2025)
4
1
19
1,141
Congratulations aux lauréats des prix poster!! Jean Solarz @InsermU1176 et Théo Sharaiha UMRS1085 !!! 🏆👏🏻👏🏻👏🏻👏🏻👏🏻
Image from Congrès de la SFTH (@SFTH_2025)
Image from Congrès de la SFTH (@SFTH_2025)
3
14
704
Load more